Investor William Ackman and Valeant Pharmaceuticals filed a notice with the Securities and Exchange Commission that they are seeking to acquire Botox maker Allergan. Ackman's capital management firm owns a 9.7% stake in Allergan.
Measurable results were seen after one treatment using a high-intensity focused ultrasound device to reduce fat around the bra line on women's backs, researchers say. The best results were seen after eight to 12 weeks, and the best candidates for the treatment have a body mass index lower than 30 with about 2.5 centimeters of isolated fat and no wounds in the target area. The device is already FDA-approved for treating abdominal fat.
Johnson & Johnson expects to receive FDA approval next year for a wrinkle-reducing injection similar to Allergan's Botox. Allergan already faces competition from Valeant's Dysport and Merz's Xeomin, but it has an 85% market share.
A greater degree of paralysis is needed to see the effects of Botox in the muscles of the upper face, according to a study in JAMA Facial Plastic Surgery. The findings indicate that dosing differences may not be due to varying degrees of susceptibility to Botox in different muscles.
Injecting tiny amounts of Botox in points around the eyebrows yielded natural-looking results that avoided forehead paralysis or upper eyelid or eyebrow ptosis, a five-year study found. The lead investigator says he would like to license the technique.